Standard BioTools Reports Second Quarter 2026 Financial Results

Losses persist despite margin gains; merger and divestiture drive near-term uncertainty.

Risk flags

• ●Revenue is declining across all major segments, with Q2 2026 revenue down to $20.1 million from $21.8 million in Q2 2025, and no forward guidance provided. This trend raises concerns about the company's ability to stabilize or grow its top line in the absence of merger-related changes.
• ●Net loss from continuing operations increased to $(21.5) million in Q2 2026 from $(17.7) million a year earlier, despite improvements in adjusted EBITDA and gross margin. Persistent losses suggest that operational improvements have not yet translated to bottom-line profitability.
• ●The company is incurring significant transaction and restructuring costs ($14.7 million and $2.8 million, respectively, in Q2 2026), which could mask underlying operating performance and may continue as strategic actions progress.
• ●Withdrawal of full-year 2026 revenue outlook removes visibility for investors, increasing uncertainty around future performance and making it difficult to assess the impact of ongoing transactions.
• ●Details on the Mass Cytometry business divestiture are lacking, with no disclosed terms, timing, or expected financial impact, leaving a gap in understanding how this will affect future results.

Bottom line

Standard BioTools Inc. remains loss-making despite improved gross margins and a sharply reduced adjusted EBITDA loss, with revenue declining across all segments. The company is in a state of transition, driven by the pending merger with Treeline Biosciences and the planned divestiture of the Mass Cytometry business, but provides minimal detail on the financial implications or timing of these strategic moves. Withdrawal of revenue guidance and persistent net losses increase uncertainty for investors, while significant transaction and restructuring costs complicate the true picture of operating performance. The strong liquidity position provides a buffer, but the lack of forward-looking financial metrics or concrete transaction details limits visibility into future value creation. Investors should focus on the actual completion and terms of the merger and divestiture, as well as any updates on revenue stabilization or profitability, as the key determinants of future performance. The most important takeaway is that near-term results remain pressured, and the investment case now hinges on successful execution of strategic transactions.

Announcement summary

(NASDAQ: LAB) Standard BioTools Inc. announced financial results for the quarter ended June 30, 2026, reporting revenue of $20.1 million. The company achieved an 84% improvement in adjusted EBITDA year-over-year, with adjusted EBITDA for the second quarter of 2026 at a loss of $2.5 million compared to a loss of $16.1 million in the prior year. Operating expenses for the second quarter of 2026 were $35.9 million, including $14.7 million in transaction costs and $2.8 million in restructuring and related charges. Net loss from continuing operations for the second quarter of 2026 was $21.5 million, compared to $17.7 million in the second quarter of 2025. The company reported cash, cash equivalents, restricted cash, short-term and long-term investments of $541.1 million as of June 30, 2026. Standard BioTools is progressing toward a merger with Treeline Biosciences, with the stockholder vote and anticipated closing before year-end 2026. The company is withdrawing its full year 2026 revenue outlook due to the pending merger.

Disagree with this article?